Rindopepimut

Identification

Name
Rindopepimut
Accession Number
DB05374  (DB05612)
Type
Small Molecule
Groups
Investigational
Description

Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015.

Structure
Thumb
Synonyms
  • Rintega
External IDs
ALT-110 / PF-04948568
Product Ingredients
Not Available
Approved Prescription Products
Not Available
Approved Generic Prescription Products
Not Available
Approved Over the Counter Products
Not Available
Unapproved/Other Products
Not Available
International/Other Brands
Not Available
Brand mixtures
Not Available
Categories
UNII
K3L4X0501F
CAS number
1108208-65-6
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in brain cancer.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

CDX-110 is an investigational immunotherapy that targets the tumor specific molecule EGFRvIII, a functional variant of the epidermal growth factor receptor (EGFR), which is a protein that has been well validated as a target for cancer therapy. This particular variant, EGFRvIII occurs in about 40 percent of Glioblastoma Multiforme (GBM) patients. It was discovered in a collaborative effort between Dr. Bert Vogelstein and Dr Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke University. Unlike EGFR, EGFRvIII is not present in normal tissues, suggesting this target will enable the development of a tumor-specific therapy for cancer patients. Furthermore, EGFRvIII is a transforming oncogene that can directly contribute to cancer cell growth. While originally discovered in GBM, the most common and aggressive form of brain cancer, the expression of EGFRvIII has also been observed in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head & neck cancers. Celldex has exclusive rights to EGFRvIII vaccines and is pursuing the development of CDX-110 for GBM therapy, as well as in other cancers through additional clinical studies.

TargetActionsOrganism
UEpidermal growth factor receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with CDX-110.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with CDX-110.Experimental, Illicit
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with CDX-110.Experimental
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with CDX-110.Experimental, Illicit
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with CDX-110.Approved
AbciximabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Abciximab.Approved
abetimusThe risk or severity of adverse effects can be increased when abetimus is combined with CDX-110.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with CDX-110.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with CDX-110.Approved
AdecatumumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with MT201.Investigational
Adefovir DipivoxilThe risk or severity of adverse effects can be increased when Adefovir Dipivoxil is combined with CDX-110.Approved, Investigational
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with CDX-110.Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with CDX-110.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with CDX-110.Experimental
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with CDX-110.Approved, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with CDX-110.Approved, Investigational
AlicaforsenThe risk or severity of adverse effects can be increased when alicaforsen is combined with CDX-110.Investigational
AlirocumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Alirocumab.Approved
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with CDX-110.Approved
ALX-0081The therapeutic efficacy of CDX-110 can be decreased when used in combination with ALX-0081.Investigational
AmatuximabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Amatuximab.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with CDX-110.Approved
AMG 108The therapeutic efficacy of CDX-110 can be decreased when used in combination with AMG-108.Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with CDX-110.Approved
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with CDX-110.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with CDX-110.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with CDX-110.Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with CDX-110.Approved
apolizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with apolizumab.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with CDX-110.Approved, Investigational
Asfotase AlfaThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Asfotase Alfa.Approved, Investigational
AtezolizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Atezolizumab.Approved
AVE9633The therapeutic efficacy of CDX-110 can be decreased when used in combination with AVE9633.Investigational
AvelumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Avelumab.Approved
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with CDX-110.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with CDX-110.Approved
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with CDX-110.Approved, Investigational
BavituximabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Bavituximab.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with CDX-110.Approved, Investigational
BectumomabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Bectumomab.Investigational
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with CDX-110.Approved
BelimumabThe risk or severity of adverse effects can be increased when Belimumab is combined with CDX-110.Approved
BenralizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Medi 563.Investigational
BenznidazoleThe risk or severity of adverse effects can be increased when Benznidazole is combined with CDX-110.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with CDX-110.Approved, Vet Approved
BevacizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Bevacizumab.Approved, Investigational
BIIB015The therapeutic efficacy of CDX-110 can be decreased when used in combination with BIIB015.Investigational
BimagrumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Bym338.Investigational
bivatuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with bivatuzumab.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with CDX-110.Approved
BlinatumomabThe risk or severity of adverse effects can be increased when Blinatumomab is combined with CDX-110.Approved
BlosozumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Ly2541546.Investigational
BococizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Pf 04950615.Investigational
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with CDX-110.Approved
BriakinumabThe risk or severity of adverse effects can be increased when Briakinumab is combined with CDX-110.Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Amg 827 is combined with CDX-110.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with CDX-110.Approved
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with CDX-110.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with CDX-110.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with CDX-110.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with CDX-110.Approved, Investigational
Capromab pendetideThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Capromab.Approved
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with CDX-110.Approved
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with CDX-110.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with CDX-110.Experimental
CatumaxomabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Catumaxomab.Investigational
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with CDX-110.Approved
CetuximabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Cetuximab.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with CDX-110.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with CDX-110.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with CDX-110.Approved
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with CDX-110.Approved, Investigational
ClazakizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Clazakizumab.Investigational
clenoliximabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with clenoliximab.Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with CDX-110.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with CDX-110.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with CDX-110.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with CDX-110.Approved, Investigational
ConcizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Concizumab.Investigational
CorticotropinThe risk or severity of adverse effects can be increased when Corticotropin is combined with CDX-110.Approved, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with CDX-110.Approved
CR002The therapeutic efficacy of CDX-110 can be decreased when used in combination with CR002.Investigational
CR011-vcMMAEThe therapeutic efficacy of CDX-110 can be decreased when used in combination with CR011-vcMMAE.Investigational
CrotedumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Regn1193.Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with CDX-110.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with CDX-110.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with CDX-110.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with CDX-110.Approved, Investigational
DacetuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Dacetuzumab.Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with CDX-110.Approved, Investigational
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with CDX-110.Approved
DalotuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Dalotuzumab.Investigational
DaratumumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Daratumumab.Approved
DasatinibThe risk or severity of adverse effects can be increased when Dasatinib is combined with CDX-110.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with CDX-110.Approved
DenosumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Deoxyspergualin is combined with CDX-110.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with CDX-110.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with CDX-110.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with CDX-110.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with CDX-110.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with CDX-110.Vet Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with CDX-110.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with CDX-110.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with CDX-110.Approved
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with CDX-110.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with CDX-110.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with CDX-110.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with CDX-110.Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with CDX-110.Approved, Investigational
DulaglutideThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Dulaglutide.Approved
DupilumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Dupilumab.Approved, Investigational
DurvalumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Medi4736.Approved
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with CDX-110.Approved, Investigational
EfalizumabThe risk or severity of adverse effects can be increased when Efalizumab is combined with CDX-110.Approved, Investigational
ElotuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Elotuzumab.Approved
EmibetuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Ly2875358.Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with CDX-110.Approved
EpratuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Epratuzumab.Investigational
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with CDX-110.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with CDX-110.Approved
EstramustineThe risk or severity of adverse effects can be increased when Estramustine is combined with CDX-110.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with CDX-110.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with CDX-110.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with CDX-110.Approved, Investigational
EtaracizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Medi 522.Investigational
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with CDX-110.Approved
EtrolizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Etrolizumab.Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with CDX-110.Approved
EvolocumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Evolocumab.Approved
FarletuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Farletuzumab.Investigational
FiclatuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Ficlatuzumab.Investigational
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with CDX-110.Approved, Investigational
FirategrastThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Sb 683699.Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with CDX-110.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with CDX-110.Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with CDX-110.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with CDX-110.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with CDX-110.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with CDX-110.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with CDX-110.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with CDX-110.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with CDX-110.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with CDX-110.Approved
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with CDX-110.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with CDX-110.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with CDX-110.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with CDX-110.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with CDX-110.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with CDX-110.Approved
FontolizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Fontolizumab.Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with CDX-110.Approved, Investigational, Withdrawn
FresolimumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Fresolimumab.Investigational
FulranumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Jnj 42160443.Investigational
GaliximabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Galiximab.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Gallium nitrate is combined with CDX-110.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with CDX-110.Approved
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with CDX-110.Approved
GevokizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Gevokizumab.Investigational
Glatiramer AcetateThe risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with CDX-110.Approved, Investigational
GlimepirideThe risk or severity of adverse effects can be increased when Glimepiride is combined with CDX-110.Approved
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with CDX-110.Approved
GS 0573The risk or severity of adverse effects can be increased when 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine is combined with CDX-110.Investigational
GuselkumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Cnto 1959.Approved
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with CDX-110.Investigational
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with CDX-110.Investigational
Human C1-esterase inhibitorThe risk or severity of adverse effects can be increased when C1 Esterase Inhibitor (Human) is combined with CDX-110.Approved
Human Varicella-Zoster Immune GlobulinThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Human Varicella-Zoster Immune Globulin.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with CDX-110.Approved, Vet Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with CDX-110.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with CDX-110.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with CDX-110.Approved
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with CDX-110.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with CDX-110.Approved
IdarucizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Idarucizumab.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with CDX-110.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with CDX-110.Approved
IGN311The therapeutic efficacy of CDX-110 can be decreased when used in combination with IGN311.Investigational
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with CDX-110.Approved
IMC-1C11The therapeutic efficacy of CDX-110 can be decreased when used in combination with IMC-1C11.Investigational
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with CDX-110.Approved, Investigational
Immune Globulin HumanThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Immune Globulin Human.Approved, Investigational
InclacumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Ro4905417.Investigational
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with CDX-110.Approved
Inotuzumab ozogamicinThe therapeutic efficacy of CDX-110 can be decreased when used in combination with CMC-544.Approved
IntetumumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Intetumumab.Investigational
IPH 2101The therapeutic efficacy of CDX-110 can be decreased when used in combination with IPH 2101.Investigational
IpilimumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Ipilimumab.Approved
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with CDX-110.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with CDX-110.Investigational
IxekizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Ixekizumab.Approved, Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with CDX-110.Approved, Nutraceutical
LabetuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Labetuzumab.Investigational
LampalizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Fcfd4514 S.Investigational
LandogrozumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Ly2495655.Investigational
LebrikizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Lebrikizumab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with CDX-110.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with CDX-110.Approved
lerdelimumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with lerdelimumab.Investigational
LexatumumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Lexatumumab.Investigational
LigelizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Qge031.Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with CDX-110.Investigational
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with CDX-110.Approved
Lorvotuzumab mertansineThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Imgn901.Investigational
LumiliximabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Lumiliximab.Investigational
MatuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Matuzumab.Investigational
MDX-1100The therapeutic efficacy of CDX-110 can be decreased when used in combination with MDX-1100.Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with CDX-110.Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with CDX-110.Approved
MEDI-528The therapeutic efficacy of CDX-110 can be decreased when used in combination with MEDI-528.Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with CDX-110.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with CDX-110.Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with CDX-110.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with CDX-110.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with CDX-110.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with CDX-110.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with CDX-110.Approved, Vet Approved
Mirvetuximab SoravtansineThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Mirvetuximab Soravtansine.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with CDX-110.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with CDX-110.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with CDX-110.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with CDX-110.Approved, Vet Approved
MORAb-009The therapeutic efficacy of CDX-110 can be decreased when used in combination with MORAb-009.Investigational
motavizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with motavizumab.Investigational
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with CDX-110.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with CDX-110.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with CDX-110.Approved
MYO-029The therapeutic efficacy of CDX-110 can be decreased when used in combination with MYO-029.Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with CDX-110.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with CDX-110.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with CDX-110.Investigational
NecitumumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Necitumumab.Approved
NelarabineThe risk or severity of adverse effects can be increased when Nelarabine is combined with CDX-110.Approved, Investigational
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with CDX-110.Approved, Investigational
nimotuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with nimotuzumab.Investigational
NivolumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Nivolumab.Approved
ObiltoxaximabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Obiltoxaximab.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with CDX-110.Approved
OfatumumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Ofatumumab.Approved
OlaratumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Olaratumab.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with CDX-110.Investigational
OlokizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Cdp6038.Investigational
OmalizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Omalizumab.Approved, Investigational
OnartuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Onartuzumab.Investigational
OregovomabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Oregovomab.Investigational
OtelixizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with TRX4.Investigational
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with CDX-110.Approved, Investigational
OzanezumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Gsk1223249.Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with CDX-110.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Palbociclib is combined with CDX-110.Approved
PalivizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Palivizumab.Approved, Investigational
PanitumumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Panobinostat is combined with CDX-110.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with CDX-110.Approved
PatritumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Patritumab.Investigational
PazopanibThe risk or severity of adverse effects can be increased when Pazopanib is combined with CDX-110.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with CDX-110.Approved, Investigational
PembrolizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with CDX-110.Approved, Investigational
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with CDX-110.Approved, Investigational
PertuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Pertuzumab.Approved
PexelizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Pexelizumab.Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with CDX-110.Approved, Investigational
PirarubicinThe risk or severity of adverse effects can be increased when Pirarubicin is combined with CDX-110.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with CDX-110.Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with CDX-110.Approved
PralatrexateThe risk or severity of adverse effects can be increased when Pralatrexate is combined with CDX-110.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with CDX-110.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with CDX-110.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with CDX-110.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with CDX-110.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with CDX-110.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with CDX-110.Experimental
PRO 140The therapeutic efficacy of CDX-110 can be decreased when used in combination with PRO 140.Investigational
PRO-542The therapeutic efficacy of CDX-110 can be decreased when used in combination with PRO-542.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with CDX-110.Approved
R1507The therapeutic efficacy of CDX-110 can be decreased when used in combination with R1507.Investigational
RacotumomabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Racotumomab.Investigational
RamucirumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Ramucirumab.Approved, Investigational
RanibizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Ranibizumab.Approved
RaxibacumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Raxibacumab.Approved
reslizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with reslizumab.Investigational
RI 624The therapeutic efficacy of CDX-110 can be decreased when used in combination with RI 624.Investigational
RIGScan CR49The therapeutic efficacy of CDX-110 can be decreased when used in combination with RIGScan CR49.Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with CDX-110.Approved
RilotumumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Rilotumumab.Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with CDX-110.Approved
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with CDX-110.Approved
RobatumumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Sch 717454.Investigational
RontalizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Rontalizumab.Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with CDX-110.Approved
SAR3419The therapeutic efficacy of CDX-110 can be decreased when used in combination with SAR3419.Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with CDX-110.Approved
SeocalcitolThe risk or severity of adverse effects can be increased when Seocalcitol is combined with CDX-110.Experimental
SeribantumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Mm 121.Investigational
SGN-40The therapeutic efficacy of CDX-110 can be decreased when used in combination with SGN-40.Investigational
SibrotuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Sibrotuzumab.Investigational
SiltuximabThe risk or severity of adverse effects can be increased when Siltuximab is combined with CDX-110.Approved
siplizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with siplizumab.Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with CDX-110.Approved, Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with CDX-110.Approved, Investigational
SteproninThe risk or severity of adverse effects can be increased when Stepronin is combined with CDX-110.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with CDX-110.Approved
SunitinibThe risk or severity of adverse effects can be increased when Sunitinib is combined with CDX-110.Approved, Investigational
SYM001The therapeutic efficacy of CDX-110 can be decreased when used in combination with SYM001.Investigational
TabalumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Ly2127399.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with CDX-110.Approved, Investigational
TanezumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Rn624.Investigational
TB-402The therapeutic efficacy of CDX-110 can be decreased when used in combination with TB-402.Investigational
Technetium Tc-99m arcitumomabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Arcitumomab.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with CDX-110.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with CDX-110.Approved
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with CDX-110.Approved
TeplizumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Teplizumab.Investigational
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with CDX-110.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with CDX-110.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with CDX-110.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with CDX-110.Approved
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with CDX-110.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with CDX-110.Approved
TNX-901The therapeutic efficacy of CDX-110 can be decreased when used in combination with TNX-901.Investigational
TocilizumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with CDX-110.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with CDX-110.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with CDX-110.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with CDX-110.Approved
TrabectedinThe risk or severity of adverse effects can be increased when Trabectedin is combined with CDX-110.Approved, Investigational
TrastuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with CDX-110.Approved
TRC105The therapeutic efficacy of CDX-110 can be decreased when used in combination with TRC105.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with CDX-110.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with CDX-110.Approved, Vet Approved
TrofosfamideThe risk or severity of adverse effects can be increased when Trofosfamide is combined with CDX-110.Investigational
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with CDX-110.Approved, Investigational
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with CDX-110.Approved
VeltuzumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Veltuzumab.Investigational
VilanterolThe risk or severity of adverse effects can be increased when Vilanterol is combined with CDX-110.Approved
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with CDX-110.Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with CDX-110.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with CDX-110.Approved
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with CDX-110.Approved, Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Lx211 is combined with CDX-110.Investigational
volociximabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with volociximab.Investigational
XmAb 2513The therapeutic efficacy of CDX-110 can be decreased when used in combination with XmAb 2513.Investigational
XTL-001The therapeutic efficacy of CDX-110 can be decreased when used in combination with XTL-001.Investigational
ZalutumumabThe therapeutic efficacy of CDX-110 can be decreased when used in combination with Zalutumumab.Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
  1. Zussman BM, Engh JA: Outcomes of the ACT III Study: Rindopepimut (CDX-110) Therapy for Glioblastoma. Neurosurgery. 2015 Jun;76(6):N17. doi: 10.1227/01.neu.0000465855.63458.0c. [PubMed:25985004 ]
External Links
Wikipedia
Rindopepimut
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1TerminatedTreatmentBrain Cancer / Brain Stem Tumors / Pontine Tumors1
Not AvailableAvailableNot AvailableRecurrent GBM1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ubiquitin protein ligase binding
Specific Function
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TG...
Gene Name
EGFR
Uniprot ID
P00533
Uniprot Name
Epidermal growth factor receptor
Molecular Weight
134276.185 Da
Drug created on November 18, 2007 11:24 / Updated on March 23, 2017 12:28